BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Files An 8-K Submission of Matters to a Vote of Security Holders

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.

Story continues below

On June5, 2018, BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) held its 2018 Annual Meeting of Stockholders (the “Annual Meeting”). A total of 176,681,294 shares of common stock were entitled to vote as of April9, 2018, the record date for the Annual Meeting. There were 136,598,234 shares of common stock present in person or represented by proxy at the Annual Meeting, at which the stockholders were asked to vote on three proposals, each of which is described in more detail in BioMarin’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April24, 2018 (the “Proxy Statement”). Set forth below are the matters acted upon by the stockholders, and the final voting results of each such proposal.

Proposal No.1: Election of Directors

Directors Elected

Vote For Withheld Broker Non-Votes

Jean-Jacques Bienaimé

123,495,784 5,454,327 7,648,123

Willard Dere, M.D.

124,803,983 4,146,128 7,648,123

Michael Grey

125,189,799 3,760,312 7,648,123

Elaine J. Heron, Ph.D.

108,702,716 20,247,395 7,648,123

Robert J. Hombach

128,431,122 518,989 7,648,123

V. Bryan Lawlis, Ph.D.

127,292,063 1,658,048 7,648,123

Alan J. Lewis, Ph.D.

126,004,210 2,945,901 7,648,123

Richard A. Meier

126,328,418 2,621,693 7,648,123

David Pyott, M.D. (Hon.)

124,709,480 4,240,631 7,648,123

Dennis J. Slamon, M.D., Ph.D.

125,157,160 3,792,951 7,648,123

Based on the votes set forth above, BioMarin’s stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner, until the director’s death, resignation or removal.

Proposal No.2: Ratification of the Selection of Independent Registered Public Accounting Firm

The ratification of the selection of KPMG LLP as BioMarin’s independent registered public accounting firm for the fiscal year ending December31, 2018, as set forth in the Proxy Statement, received the following votes:

For

Against

Abstain

135,307,381

908,169 382,684

Based on the votes set forth above, BioMarin’s stockholders ratified the selection of KPMG LLP as BioMarin’s independent registered public accounting firm to serve for the year ending December31, 2018.

Proposal No.3: Advisory Vote on the Compensation of the Company’s Named Executive Officers

The advisory (non-binding) vote to approve the compensation of BioMarin’s named executive officers, as set forth in the Proxy Statement, received the following votes:

For

Against

Abstain

Broker

Non-Votes

71,473,926

57,063,780 412,405 7,648,123

Based on the votes set forth above, BioMarin’s stockholders approved, on an advisory basis, the compensation of BioMarin’s named executive officers, as set forth in the Proxy Statement.


About BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Its products in clinical development include Kyndrisa, Pegvaliase, Reveglucosidase alfa, Vosoritide (formerly BMN 111), Cerliponase alfa, BMN 044, BMN 045, BMN 053 and BMN 270. Vimizim is an enzyme replacement therapy for the treatment of mucopolysaccharidosis type IV (MPS IV A). Naglazyme is a recombinant form of N-acetylgalactosamine 4-sulfatase (arylsulfatase B) indicated for patients with mucopolysaccharidosis VI (MPS VI). Kuvan is a synthetic oral form of 6R-BH4 indicated for patients with phenylketonuria (PKU).

An ad to help with our costs